Profile data is unavailable for this security.
About the company
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; the biologic Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency, and Capeserod, a selective 5-HT4 receptor partial agonist which the Company is developing as a gastroparesis therapeutic.
- Revenue in USD (TTM)0.00
- Net income in USD-6.44m
- Incorporated2014
- Employees15.00
- LocationEntero Therapeutics Inc777 Yamato Road, Suite 502BOCA RATON 33431United StatesUSA
- Phone+1 (561) 589-7020
- Websitehttps://enterothera.com/
More ▼
Mergers & acquisitions
| Acquired company | ENTO:NAQ since announced | Transaction value |
|---|---|---|
| ImmunogenX Inc | -92.28% | -- |
Data delayed at least 15 minutes, as of Sep 25 2024 15:01 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endonovo Therapeutics Inc | 255.72k | -4.40m | 515.88k | 0.00 | -- | -- | -- | 2.02 | -0.0652 | -0.0652 | 0.0003 | -0.072 | 0.2256 | -- | -- | -- | -388.54 | -303.26 | -- | -- | 96.21 | 74.38 | -1,722.26 | -5,956.27 | -- | -1.38 | -- | -- | 85.15 | -- | -495.02 | -- | -- | -- |
| Herborium Group, Inc. | 340.33k | -318.65k | 545.97k | 2.00 | -- | -- | -- | 1.60 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
| International Stem Cell Corp | 8.32m | -529.00k | 552.30k | 29.00 | -- | -- | -- | 0.0664 | -0.0661 | -0.0661 | 1.04 | 0.0355 | 1.46 | 2.54 | 11.31 | 286,965.50 | -12.02 | -29.22 | -84.86 | -73.82 | 58.62 | 59.49 | -8.22 | -21.01 | 0.4785 | -3.94 | 0.9254 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
| Capstone Therapeutics Corp | 0.00 | -358.00k | 580.00k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
| GlobeStar Therapeutics Corp | 0.00 | -1.98m | 581.46k | -- | -- | -- | -- | -- | -0.0023 | -0.0023 | 0.00 | -0.0015 | 0.00 | -- | -- | -- | -38,103.72 | -4,657.88 | -- | -- | -- | -7,790.20 | -- | -2,834,410.00 | -- | -21.00 | -- | -- | -- | -- | -31.01 | -- | -- | -- |
| Yield10 Bioscience Inc | 750.00k | -12.70m | 604.39k | 29.00 | -- | -- | -- | 0.8059 | -135.92 | -135.92 | 1.95 | -9.71 | 0.1697 | -- | -- | 25,862.07 | -287.44 | -91.26 | -- | -108.09 | -- | -- | -1,693.60 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
| VBI Vaccines Inc | 9.41m | -83.99m | 613.80k | 131.00 | -- | -- | -- | 0.0652 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 782.38k | 15.00 | -- | 0.0396 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Aditxt Inc | 329.75k | -43.31m | 815.33k | 47.00 | -- | 0.0687 | -- | 2.47 | -77.20 | -77.20 | 0.303 | 3.29 | 0.0185 | 0.6082 | 0.8393 | 7,015.96 | -242.33 | -192.78 | -1,548.63 | -321.59 | -46.09 | -- | -13,105.77 | -7,208.65 | 0.0458 | -3.53 | 0.5084 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Molecular Pharmacology (USA) Ltd | 0.00 | -105.18k | 899.60k | 0.00 | -- | -- | -- | -- | -0.0009 | -0.0009 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -976.60 | -1,219.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.29 | -- | -- | -- |
| Emmaus Life Sciences Inc | 19.97m | -5.26m | 957.98k | 51.00 | -- | -- | -- | 0.048 | -0.0824 | -0.0824 | 0.2506 | -0.8927 | 0.5239 | 0.5247 | 3.93 | 391,529.40 | -13.79 | -- | -- | -- | 95.48 | -- | -26.32 | -- | 0.1153 | -0.1451 | -- | -- | 60.94 | -- | 64.87 | -- | -- | -- |
| Genprex Inc | 0.00 | -26.14m | 1.03m | 26.00 | -- | 0.2331 | -- | -- | -16.04 | -16.04 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -232.21 | -92.06 | -318.88 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
Data as of Sep 25 2024. Currency figures normalised to Entero Therapeutics Inc's reporting currency: US Dollar USD
1.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 27.00k | 1.09% |
| Geode Capital Management LLCas of 30 Jun 2024 | 16.15k | 0.65% |
| Tower Research Capital LLCas of 31 Mar 2024 | 2.39k | 0.10% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 12.00 | 0.00% |
| U.S. Bank NA (Cincinnati Ohio Investment Management)as of 30 Jun 2024 | 1.00 | 0.00% |
| Kathleen S. Wright Associates, Inc.as of 30 Jun 2024 | 1.00 | 0.00% |
| Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 1.00 | 0.00% |
| UBS Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
